Identifying & Exploiting Immune Checkpoint Targets for Next Generation Cancer Therapies
Tumors can progress only if they evade the immune system. Many tumors have evolved mechanisms of exploiting cancer-preventing 'checkpoints' in the immune system to their advantage.
Therapeutic antibodies targeting these checkpoints restore anti-tumor immune function allowing the immune system to recognise and kill cancer cells.
OBT leverages detailed mapping of cell surface proteins expressed on cancer cells, normal tissue cells, tumor-infiltrating lymphocytes (TILs) and healthy immune cells to identify molecules involved in tumor-immune cell cross-talk. OBT has identified novel targets and pathways involved in immune surveillance and tumor immune evasion thereby generating a unique insight into the cancer–immune cell interface. OBT is in the process of translating several of these molecules into powerful immune-modulatory therapies targeting multiple immune cells and cancer types.
Therapeutic antibodies targeting these checkpoints restore anti-tumor immune function allowing the immune system to recognise and kill cancer cells.
OBT leverages detailed mapping of cell surface proteins expressed on cancer cells, normal tissue cells, tumor-infiltrating lymphocytes (TILs) and healthy immune cells to identify molecules involved in tumor-immune cell cross-talk. OBT has identified novel targets and pathways involved in immune surveillance and tumor immune evasion thereby generating a unique insight into the cancer–immune cell interface. OBT is in the process of translating several of these molecules into powerful immune-modulatory therapies targeting multiple immune cells and cancer types.
New receptor-ligand immune escape axis escape mechanism
OBT has discovered and characterised a novel cancer immune escape mechanism independent of PD-1/PD-L1 axis. OBT is targeting this novel ligand-receptor immune escape axis with IO therapies in order to reactivate the killer cells of the immune system (CTLs and NK cells) and boost anti-cancer immune response in patients."
OBT has discovered and characterised a novel cancer immune escape mechanism independent of PD-1/PD-L1 axis. OBT is targeting this novel ligand-receptor immune escape axis with IO therapies in order to reactivate the killer cells of the immune system (CTLs and NK cells) and boost anti-cancer immune response in patients."
